CDK9 and cancer: Hence, a potential strategy for inhibiting the involvement of CDK9 in the above pathological conditions, especially apoptosis and angiogenesis of cancers (Kryštof et al., 2011; Polier et al., 2011), is to disrupt its binding to its cyclin partner.